Many plans impose prior authorizations, quantity limits, or tiering requirements that delay treatment or force patients to absorb significant out-of-pocket costs
While the medications, which were first approved for diabetes management before gaining attention for weight loss, have resulted in positive health outcomes for many employees, they also have been a costly consideration for HR and benefits leaders
Kamerkar, S
Wegovy, semaglutida, acta como un agonista del receptor GLP-1, mejorando el control glucmico y promoviendo la secrecin de insulina
Metabolic and Lipid Effects Study (JCEM, 2026) Study Title: Retatrutide and lipid and metabolite profiles in participants with obesity with or without type 2 diabetes Link: [academic.oup.com] Key Findings: Demonstrated improvements in biomarkers associated with insulin resistance and cardiovascular risk
attributing that to cagrilintide alone overstates the stand-alone case